On October 3, 2024, Mangoceuticals, Inc., also known as MangoRx, announced the launch of 'TRIM,' an oral dissolvable tablet for weight loss containing Tirzepatide, a dual GIP and GLP-1 receptor agonist. The product, priced at $399 per month, offers a non-invasive alternative to injectable therapies and is available through MangoRx's telemedicine platform. Clinical trials, including the phase 3 SURMOUNT-1 and SURMOUNT-4, have demonstrated Tirzepatide's effectiveness in achieving and maintaining significant weight loss. The launch of TRIM aligns with MangoRx's strategy to expand its presence in the weight management market, which is projected to grow significantly in the coming years. The company, which specializes in men's health and wellness products, also offers Semaglutide-based weight loss treatments. MangoRx's products are available with a doctor's prescription and are shipped discreetly to patients. The announcement was made via a press release filed with the SEC as part of a Form 8-K report.

On October 3, 2024, Mangoceuticals, Inc., also known as MangoRx, announced the launch of 'TRIM,' an oral dissolvable tablet for weight loss containing Tirzepatide, a dual GIP and GLP-1 receptor agonist. The product, priced at $399 per month, offers a non-invasive alternative to injectable therapies and is available through MangoRx's telemedicine platform. Clinical trials, including the phase 3 SURMOUNT-1 and SURMOUNT-4, have demonstrated Tirzepatide's effectiveness in achieving and maintaining significant weight loss. The launch of TRIM aligns with MangoRx's strategy to expand its presence in the weight management market, which is projected to grow significantly in the coming years. The company, which specializes in men's health and wellness products, also offers Semaglutide-based weight loss treatments. MangoRx's products are available with a doctor's prescription and are shipped discreetly to patients. The announcement was made via a press release filed with the SEC as part of a Form 8-K report.